

OCT 16 2006

Atty. Dkt. No. 071949-5914

## IN THE CLAIMS

Please amend the claims as shown below:

1. (Currently amended) A method of diagnosing sepsis in a human subject, comprising:

~~comparing~~ determining a concentration of at least one analyte in a test sample from said human subject;

comparing the concentration of each said analyte(s) to a corresponding reference concentration selected to indicate the presence or absence of sepsis, wherein said reference concentration is of said at least one analyte in a reference range that was determined for by using one or more control samples obtained from one or more human subjects not suffering from sepsis, wherein the

provided that at least one of said analyte(s) is selected from the group consisting of: IL-1 Ra, MCP-1, myeloid progenitor inhibitory factor-1 ("MPIF-1"), wherein an elevated concentration of MPIF-1 in the test sample relative to the reference concentration is indicative of the presence of sepsis in the human subject ~~TNF-R1, MIG, BLC, HVEM, IL-15, MCP-2, M-CSF, MIP-3b, MMP-9, PARC, and ST-2; and~~

diagnosing sepsis in the human subject using the result(s) of said comparing step if the concentration of the at least one analyte is elevated in the test sample relative to the reference range.

2. (Original) The method of claim 1 wherein said samples comprise blood.

3. (Original) The method of claim 1 wherein said samples comprise serum.

4. (Original) The method of claim 1 wherein said samples comprise plasma.

5. (Currently amended) The method of claim 1 wherein the further provided that at least one analyte comprises is interleukin 1 receptor antagonist ("IL-1 Ra").

Atty. Dkt. No. 071949-5914

6. (Currently amended) The method of claim 1 wherein the further provided that at least one analyte ~~comprises~~ is monocyte chemotactic protein-1 ("MCP-1").
7. (Cancelled)
8. (Currently amended) The method of claim 1 wherein the further provided that at least one analyte ~~comprises~~ is tumor necrosis factor receptor-1 ("TNF-R1").
9. (Currently amended) The method of claim 1 wherein the further provided that at least one analyte ~~comprises~~ is monokine induced by interferon gamma ("MIG").
10. (Currently amended) The method of claim 1 wherein the further provided that at least one analyte ~~comprises~~ is B-lymphocyte chemoattractant ("BLC").
11. (Currently amended) The method of claim 1 wherein the further provided that at least one analyte ~~comprises~~ is herpes virus entry factor ("HVEM").
12. (Currently amended) The method of claim 1 wherein the further provided that at least one analyte ~~comprises~~ is interleukin-15 ("IL-15").
13. (Currently amended) The method of claim 1 wherein the further provided that at least one analyte ~~comprises~~ is monocyte chemotactic protein-2 ("MCP-2").
14. (Currently amended) The method of claim 1 wherein the further provided that at least one analyte ~~comprises~~ is macrophage colony stimulating factor ("M-CSF").
15. (Currently amended) The method of claim 1 wherein the further provided that at least one analyte ~~comprises~~ is monocyte chemotactic protein-3 beta ("MIP-3 $\beta$ ").
16. (Currently amended) The method of claim 1 wherein the further provided that at least one analyte ~~comprises~~ is matrix metalloproteinase-9 ("MMP-9").

Atty. Dkt. No. 071949-5914

17. (Currently amended) The method of claim 1 wherein ~~the~~ further provided that at least one analyte ~~comprises~~ is pulmonary and activation-regulated chemokine ("PARC").

18. (Currently amended) The method of claim 1 wherein ~~the~~ further provided that at least one analyte ~~comprises~~ is interleukin 1 receptor antagonist ("ST-2").

19. (Currently amended) The method of claim 1 wherein sepsis is diagnosed if at least two of said analytes in said test sample are elevated relative to the corresponding reference concentrations.

20. (Currently amended) The method of claim 1 wherein sepsis is diagnosed if at least three of said analytes in said test sample are elevated relative to the corresponding reference concentrations.

21. (Currently amended) The method of claim 1 wherein sepsis is diagnosed if at least four of said analytes in said test sample are elevated relative to the corresponding reference concentrations.

22. (Currently amended) The method of claim 1 wherein sepsis is diagnosed if at least five of said analytes in said test sample are elevated relative to the corresponding reference concentrations.

23. (Currently amended) The method of claim 1 wherein sepsis is diagnosed if at least six of said analytes in said test sample are elevated relative to the corresponding reference concentrations.

24-95. (Cancelled)

96. (New) The method of claim 1, further provided that at least one analyte is selected from the group consisting of epidermal growth factor ("EGF"), epithelial cell-derived neutrophil activating peptide ("ENA-78"), eotaxin ("EOT"), growth-related oncogene beta ("Gro- $\beta$ "), interleukin-1 beta ("IL-1 $\beta$ "), Leptin, macrophage migration inhibitory factor ("MIF"),

Atty. Dkt. No. 071949-5914

macrophage inflammatory protein-1 alpha ("MIP-1 $\alpha$ "), oncostatin M ("OSM"), Protein C, P-Selectin, and hemofiltrate CC chemokine 4 ("HCC4").

97. (New) The method of claim 96 wherein further provided that at least one analyte is EGF.
98. (New) The method of claim 96 wherein further provided that at least one analyte is ENA-78.
99. (New) The method of claim 96 wherein further provided that at least one analyte is EOT.
100. (New) The method of claim 96 wherein further provided that at least one analyte is Gro- $\beta$ .
101. (New) The method of claim 96 wherein further provided that at least one analyte is IL-1 $\beta$ .
102. (New) The method of claim 96 wherein further provided that at least one analyte is Leptin.
103. (New) The method of claim 96 wherein further provided that at least one analyte is MIF.
104. (New) The method of claim 96 wherein further provided that at least one analyte is MIP-1 $\alpha$ .
105. (New) The method of claim 96 wherein further provided that at least one analyte is OSM.
106. (New) The method of claim 96 wherein further provided that at least one analyte is Protein C.
107. (New) The method of claim 96 wherein further provided that at least one analyte is P-Selectin.
108. (New) The method of claim 96 wherein further provided that at least one analyte is HCC4.